放疗后三阴性乳腺癌细胞中半乳糖凝集素 9 的表达增强：对靶向治疗的影响。
Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
发表日期：2024 Jul 30
作者：
Cédric Lerévérend, Nour Kotaich, Lucille Cartier, Manon De Boni, Sarah Lahire, Caroline Fichel, Charlotte Thiebault, Eva Brabencova, Célia Maquin, Elodie Barbosa, Laurent Corsois, Judicael Hotton, Sofiane Guendouzen, Philippe Guilbert, Aude-Marie Lepagnol-Bestel, Laurence Cahen-Doidy, Jacqueline Lehmann-Che, Jérôme Devy, Armand Bensussan, Sébastien Le Jan, Arnaud Pommier, Yacine Merrouche, Richard Le Naour, Stéphane Vignot, Stephane Potteaux
来源：
INTERNATIONAL JOURNAL OF CANCER
摘要：
预计三阴性乳腺癌（TNBC）免疫疗法的开发将得到优化。我们研究了放射后半乳糖凝集素 9 (Gal-9) 的表达，并评估了有或没有放射治疗时其靶向的不同影响。接受新辅助放疗的 TNBC 患者的肿瘤切除显示，与基线水平相比，Gal-9 水平较高，仅在无反应患者中。还发现放射后 TNBC 肿瘤活检和细胞系中 Gal-9 的表达增加。我们研究了小鼠放疗后靶向 Gal-9 的治疗优势。将经照射的4T1细胞或对照未照射的4T1细胞注射到BALB/c小鼠中。抗 Gal-9 抗体治疗仅在注射受辐射 4T1 细胞的小鼠中减少肿瘤进展。这项概念验证研究表明，Gal-9 可以被视为 TNBC 放疗后的动态生物标志物，并表明 Gal-9 诱导的过度表达可能代表为 TNBC 患者开发新治疗策略的机会。© 2024 作者（ s）。约翰·威利出版的《国际癌症杂志》
Optimizations are expected in the development of immunotherapy for the treatment of Triple-negative breast cancer (TNBC). We studied the expression of galectin-9 (Gal-9) after irradiation and assessed the differential impacts of its targeting with or without radiotherapy. Tumor resections from TNBC patients who received neoadjuvant radiotherapy revealed higher levels of Gal-9 in comparison to their baseline level, only in non-responder patients. Gal-9 expression was also found to be increased in TNBC tumor biopsies and cell lines after irradiation. We investigated the therapeutic advantage of targeting Gal-9 after radiotherapy in mice. Irradiated 4T1 cells or control non-irradiated 4T1 cells were injected into BALB/c mice. Anti-Gal-9 antibody treatment decreased tumor progression only in mice injected with irradiated 4T1 cells. This proof-of-concept study demonstrates that Gal-9 could be considered as a dynamic biomarker after radiotherapy for TNBC and suggests that Gal-9 induced-overexpression could represent an opportunity to develop new therapeutic strategies for TNBC patients.© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.